Cargando…

Novel agents for advanced pancreatic cancer

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akinleye, Akintunde, Iragavarapu, Chaitanya, Furqan, Muhammad, Cang, Shundong, Liu, Delong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741843/ https://www.ncbi.nlm.nih.gov/pubmed/26369833

Ejemplares similares

Novel ALK inhibitors in clinical use and development
por: Iragavarapu, Chaitanya, et al.
Publicado: (2015)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

STAT inhibitors for cancer therapy
por: Furqan, Muhammad, et al.
Publicado: (2013)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
por: Parikh, Kaushal, et al.
Publicado: (2014)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
por: Tan, Jiahuai, et al.
Publicado: (2010)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Novel agents for chronic lymphocytic leukemia
por: Wu, Mei, et al.
Publicado: (2013)

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
por: Cang, Shundong, et al.
Publicado: (2008)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
por: Linder, Katherine, et al.
Publicado: (2017)

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
por: Cang, Shundong, et al.
Publicado: (2009)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
por: Aujla, Amandeep, et al.
Publicado: (2018)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells
por: Cang, Shundong, et al.
Publicado: (2014)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells
por: Cang, Shundong, et al.
Publicado: (2016)

Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells
por: Liu, Katherine, et al.
Publicado: (2013)

A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma
por: Yu, Yang, et al.
Publicado: (2018)

Recent advances and novel agents for gastrointestinal stromal tumor (GIST)
por: Lamba, Gurpreet, et al.
Publicado: (2012)

Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells
por: Chen, Yamei, et al.
Publicado: (2016)

Current management and novel agents for malignant melanoma
por: Lee, Byung, et al.
Publicado: (2012)

Cancer-related long noncoding RNAs show aberrant expression profiles and competing endogenous RNA potential in esophageal adenocarcinoma
por: Yu, Yang, et al.
Publicado: (2019)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
por: Zhu, Xiongpeng, et al.
Publicado: (2010)

Evaluation of adjuvant therapy for T1-2N1miM0 breast cancer without further axillary lymph node dissection
por: Li, Baiyu, et al.
Publicado: (2023)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets
por: Liu, Guanjun, et al.
Publicado: (2021)

Development of human prostate cancer stem cells involves epigenomic alteration and PI3K/AKT pathway activation
por: Wu, Jingjing, et al.
Publicado: (2020)

Myocarditis Concurrent with Sweet Syndrome: A Presentation of Acute Myeloid Leukemia
por: Burkeen, Christopher G., et al.
Publicado: (2021)

Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: A SEER-based analysis
por: Feng, Xiao, et al.
Publicado: (2019)

Recent Advances in the Discovery of Novel Antiprotozoal Agents
por: Lee, Seong-Min, et al.
Publicado: (2019)

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
por: Zhang, Yiyin, et al.
Publicado: (2018)

MiR-138–5p inhibits prostate cancer cell proliferation and chemoresistance by targeting APOBEC3B
por: Liu, Lina, et al.
Publicado: (2023)

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
por: Hou, Jing-Zhou, et al.
Publicado: (2021)

Advances in pancreatic cancer biomarkers
por: Hasan, Syed, et al.
Publicado: (2019)

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
por: Pan, Chongxian, et al.
Publicado: (2020)

A novel event-free survival endpoint in locally advanced pancreatic cancer
por: Hammel, Pascal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tuovle8npt5di2mvf481cnulfa